Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials

Peto, R., Davies, C., Godwin, J., Gray, R., Pan, H. C., Clarke, M., Cutter, D., Darby, S., McGale, P., Taylor, C., Wang, Y. C., Bergh, J., Di Leo, A., Albain, K., Swain, S., Piccart, M., & Pritchard, K. (2012). Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. The Lancet, 379(9814), 432-444. https://doi.org/10.1016/S0140-6736(11)61625-5

[1]  V. Hasselblad,et al.  Introduction and Methods , 2013 .

[2]  J. Cuzick,et al.  Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  D. Bedognetti,et al.  Concurrent vs sequential adjuvant chemotherapy and hormone therapy in breast cancer: a multicenter randomized phase III trial. , 2011, Journal of the National Cancer Institute.

[4]  M. Piccart,et al.  Long-term toxic effects of adjuvant chemotherapy in breast cancer. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  R Peto,et al.  Current misconception 3: that subgroup-specific trial mortality results often provide a good basis for individualising patient care , 2011, British Journal of Cancer.

[6]  A. Luini,et al.  Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features , 2010, Breast Cancer Research and Treatment.

[7]  Jack Cuzick,et al.  Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Annuska M. Glas,et al.  The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer , 2010, Breast Cancer Research and Treatment.

[9]  J. Cuzick,et al.  Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  S. Martino,et al.  Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial , 2009, The Lancet.

[11]  C. Sotiriou,et al.  Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures , 2008, Breast Cancer Research.

[12]  Arrate Plazaola,et al.  Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. , 2008, Journal of the National Cancer Institute.

[13]  E. Perez,et al.  Weekly paclitaxel in the adjuvant treatment of breast cancer. , 2008, The New England journal of medicine.

[14]  Fatima Cardoso,et al.  The MINDACT trial: The first prospective clinical validation of a genomic tool , 2007, Molecular oncology.

[15]  S. Swain,et al.  Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Sparano,et al.  TAILORx: trial assigning individualized options for treatment (Rx). , 2006, Clinical breast cancer.

[17]  D. Berry,et al.  Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. , 2006, JAMA.

[18]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.

[19]  C. Osborne,et al.  Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  J. Bergh,et al.  Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[22]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[23]  H. Marks.  A conversation with Paul Meier , 2004 .

[24]  Richard L Schilsky,et al.  Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  M. Bonetti,et al.  Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial. , 2002, Journal of the National Cancer Institute.

[26]  H. Mouridsen,et al.  Evidence of a castration-mediated effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[28]  Relevance of breast cancer hormone receptors and other factors to the effi cacy of adjuvant tamoxifen : patient-level meta-analysis of randomised trials , 2011 .

[29]  Robert B Livingston,et al.  Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. , 2010, The Lancet. Oncology.

[30]  A. Tres,et al.  Epirubicin-cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 study. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  J. Haerting,et al.  Gene-expression signatures in breast cancer. , 2003, The New England journal of medicine.